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Invasive Aspergillosis (IA) is an opportunistic infection caused by Aspergillus, a
ubiquitously present airborne pathogenic mold. A growing number of studies suggest a
major host genetic component in disease susceptibility. Here, we evaluated whether 14
single-nucleotide polymorphisms withinNFκB1,NFκB2, RelA, RelB, Rel, and IRF4 genes
influence the risk of IA in a population of 834 high-risk patients (157 IA and 677 non-IA)
recruited through a collaborative effort involving the aspBIOmics consortium and four
European clinical institutions. No significant overall associations between selected SNPs
and the risk of IA were found in this large cohort. Although a hematopoietic stem cell
transplantation (HSCT)-stratified analysis revealed that carriers of the IRF4rs12203592T/T
genotype had a six-fold increased risk of developing the infection when compared with
those carrying the C allele (ORREC = 6.24, 95%CI 1.25–31.2, P= 0.026), the association
of this variant with IA risk did not reach significance at experiment-wide significant
threshold. In addition, we found an association of the IRF4AATC and IRF4GGTC haplotypes
(not including the IRF4rs12203592T risk allele) with a decreased risk of IA but the magnitude
of the association was similar to the one observed in the single-SNP analysis, which
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indicated that the haplotypic effect on IA risk was likely due to the IRF4rs12203592 SNP.
Finally, no evidence of significant interactions among the genetic markers tested and the
risk of IA was found. These results suggest that the SNPs on the studied genes do not
have a clinically relevant impact on the risk of developing IA.
Keywords: Invasive Aspergillosis, genetic polymorphisms, susceptibility, NFκB-related genes, interaction
INTRODUCTION
Invasive Aspergillosis (IA) is an opportunistic infection often
caused by species of Aspergillus, a common saprophytic
filamentous fungus that is ubiquitously present in the
environment. The LIFE initiative has estimated that around
30 million patients worldwide are at high risk of developing
IA every year and over 200,000 patients develop the infection
annually. Despite the substantial improvement in efficacy of
newly developed anti-fungal drugs (mainly azoles alone or
in combination with other antifungal drugs), IA continues to
be a life-threatening infection in an increasing proportion of
immunocompromised or critically ill subjects (Neofytos et al.,
2009; Steinbach et al., 2012). IA is frequently encountered in
patients of intensive care (Meersseman et al., 2007) and solid
organ transplantation units (Singh et al., 2013) but also among
those patients who undergo allogeneic hematopoietic stem cell
transplantation (allo-HSCT) or are diagnosed either with acute
myeloid leukemia (AML) or acute lymphoid leukemia (ALL)
and receive high-dose chemotherapy regimens (Steinbach et al.,
2012; Neofytos et al., 2013a,b).
Althoughmajor clinical risk factors for IA have been identified
(Kousha et al., 2011) and the management of high-risk patients
has been improved through the optimization of prevention
strategies and early initiation of anti-fungal prophylaxis,
mortality rates for IA remain still today unacceptably high
(up to 30–60%; Neofytos et al., 2009; Steinbach et al., 2012;
Karthaus and Buchheidt, 2013). These observational findings
suggest that additional factors may contribute to the risk of
developing IA. In this regard, a growing number of studies
have suggested that host genetic polymorphisms within or near
immune-related genes may contribute to determine the risk of
developing the infection (Kesh et al., 2005; Sainz et al., 2007a,b,
2008a,b, 2010, 2012; Bochud et al., 2008; Mezger et al., 2008;
Ramaprakash et al., 2009; Cunha et al., 2010, 2011, 2014; Chai
et al., 2011; Grube et al., 2013; Stappers et al., 2014; Wojtowicz
et al., 2015a,b). Interestingly, a substantial proportion of the
susceptibility markers identified to date for IA are located
in genes directly or indirectly implicated in the activation of
the nuclear factor-kappa B (NFκB) signaling pathway, which
suggests a relevant role of this biological route in determining the
risk of developing this fungal infection. In particular, it has been
reported that single nucleotide polymorphisms (SNPs) within
toll-like receptors (TLRs; Mambula et al., 2002; Kesh et al., 2005;
Bochud et al., 2008; Pamer, 2008; Ramaprakash et al., 2009;
Carvalho et al., 2012; Grube et al., 2013), C-type lectins (Cunha
et al., 2010; Chai et al., 2011; Sainz et al., 2012), PTX3 (Cunha
et al., 2014), and tumor necrosis factor receptors (TNFRs; Sainz
et al., 2007b, 2010), which are pathogen recognition receptors
(PRRs) that often culminate in the activation of NFκB pathway,
may render patients more susceptible to develop IA.
Based on these findings but also those that have demonstrated
that NFκB1 (p105/p50), NFκB2 (p100/p52), Rel A (p65), RelB,
c-Rel genes may form homo- and hetero-dimers to regulate the
activation of the canonical and non-canonical NFκB pathways
(Moynagh, 2005; Gilmore, 2006; Hoffmann et al., 2006; Schlitzer
et al., 2013; Bajaña et al., 2016) but also IRF4-dependent immune
responses (Boddicker et al., 2015), we hypothesized that the
presence of common genetic polymorphisms within NFκB1,
NFκB2, RelA, RelB, Rel, and IRF4 genes might influence the
risk of developing IA in high-risk patients. Thus, the aim of
the present study was to investigate the relationship between 14
single nucleotide polymorphisms within these genes and the risk
of IA but also to determine whether these variants could interact
with each other to modify the risk of developing the infection.
MATERIAL AND METHODS
Study Population
Eight hundred and thirty-four high-risk European Caucasian
patients undergoing allo-HSCT or being diagnosed with acute
myeloid leukemia (AML) or acute lymphoid leukemia (ALL)
and receiving intensive remission-induction chemotherapy were
recruited in this case-control population-based study (Lupiañez
et al., 2015). Three hundred and thirty-five patients were
ascertained from the aspBIOmics consortium (http://www.
aspbiomics.eu) whereas 341 patients were collected from two
Spanish medical institutions (University Hospital of Salamanca
and Clinic University Hospital of Valencia) and through a
Spanish multicenter clinical trial (PCRAGA, EU clinical trial
number: 2010-019406-17; Aguado et al., 2015). In addition, 148
patients were recruited from two Italian medical institutions
(Università Cattolica del S. Cuore, Rome; and University of
Modena and Reggio Emilia, AOU Policlinico, Modena). Of those
834 patients, a total of 157 patients were diagnosed with proven
or probable IA according to the updated EORTC/MSG criteria
(De Pauw et al., 2008) whereas the remaining 677 patients did
not show any sign of fungal infection.
SNP Selection and Genotyping
Fourteen polymorphisms within the NFκB1, NFκB2, RelA, RelB,
Rel, and IRF4 genes were selected to be genotyped in the whole
population (Table 1). SNP selection was based on previously
reported associations with cancer (Curtin et al., 2010; Do et al.,
2010; Han et al., 2011; Slattery et al., 2011; Seufert et al., 2013;
Wang et al., 2014) and immune-related diseases including
infections (Chen et al., 2006, 2016; Gregersen et al., 2009; Trynka
et al., 2009; Eyre et al., 2010; Varadé et al., 2011; Bowes et al.,
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TABLE 1 | NFκB-related polymorphisms.
Gene dbSNP Chr. Location/Aa Nucleotide Effect-allele
rs# change substitution
NFκB1 rs4648110 4 Intronic A/T A
NFκB2 rs12769316 10 Near gene A/G A
rs1056890 10 Near gene C/T T
rs11574851 10 N698N C/T T
REL rs13031237 2 Intronic G/T T
rs842647 2 Intronic A/G G
rs13017599 2 Near gene A/G A
RELA rs7119750 11 Intronic C/T T
RELB rs2288918 19 Intronic C/T C
IRF4 rs872071 6 3′-UTR A/G G
rs1877175 6 3′-UTR A/G A
rs1050975 6 3′-UTR A/G G
rs7768807 6 3′-UTR C/T C
rs12203592 6 Intronic C/T T
SNP, Single Nucleotide Polymorphism; Aa, Aminoacid.
2012; Ellinghaus et al., 2012; Ali et al., 2013; Leung et al., 2014;
Pan et al., 2015) but also because their potential functionality
according to the Haploreg (http://www.broadinstitute.org/
mammals/haploreg/haploreg.php) and ENCODE annotation
data (https://genome.ucsc.edu/ENCODE/). The genotyping of
the selected polymorphisms was carried out at GENYO (Center
for Genomics and Oncological Research: Pfizer/University of
Granada/Andalusian Regional Government, Granada, Spain)
using KASPar R© assays (LGC Genomics, Hoddesdon, UK)
according to manufacturer’s instructions. For internal quality
control, 5% of samples were randomly selected and included as
duplicates. Concordance between the original and the duplicate
samples for the 14 SNPs was ≥99.0%. Call rates for all SNPs
were≥90.0% with the exception of the IRF4rs872071 SNP that was
excluded from further analysis.
Statistical Analysis
The Hardy-Weinberg Equilibrium (HWE) test was performed
in the control group (non-IA patients) by a standard observed-
expected chi-square (χ2). Logistic regression analysis adjusted
for age, sex, country of origin, allo-HSCT, underlying disease
and prophylaxis status was used to assess the main effects
of the selected SNPs on IA risk. We also performed gene-
HSCT interaction analyses to determine whether the association
between SNPs and IA was of similar magnitude in HSCT (at
highest risk) and non-HSCT patients. Although the selection
of variables for adjustment was based on well-established
risk factors for IA, the partial availability of data regarding
prophylaxis status, type of chemotherapy, immunosuppressive
drugs (HSCT), HLA mismatch (HSCT), or CMV status did not
allow us to assess the impact of these factors on the genetic
associations tested. Statistical power of the overall and HSCT-
stratified analyses was estimated using Quanto software (http://
hydra.usc.edu/gxe/). All tests were conducted using the statistical
software SPSS (v.20) and STATA (v.12) for MAC.
In order to account formultiple comparisons, we calculated an
adjusted significance level using the Meff method (Nyholt, 2004)
but also considering the number of inheritance models tested
(codominant, dominant, recessive, and log-additive). Thus, the
significant threshold used for the main effect analysis was 0.001
([0.05]/13 independent genetic markers]/4 inheritance models).
Linkage Disequilibrium (LD) and Haplotype
Analysis
Haplotype blocks were constructed from the genotyping data
of the non-IA control group using the SNPtool (http://www.
dkfz.de/de/molgen_epidemiology/tools/SNPtool.html; Chen
et al., 2009) and the Haploview software (v.4.2). Selected
polymorphisms within the same locus were not in linkage
disequilibrium ensuring that these variants represented
independent variability signals (Supplementary Figure 1).
In addition to the analysis based on a single SNP, we
performed haplotype frequency estimation and haplotype
association analysis using SNPStats (http://bioinfo.iconcologia.
net/SNPstats). Haplotype frequencies were determined using the
Expectation-maximization (EM) algorithm and the minimum
haplotype frequency was set at 0.01, therefore assessing
association for common haplotypes.
eQTL Analysis
We also assessed whether selected polymorphisms correlated
with mRNA expression in the publicly available eQTL IGV
browser for primary cells (http://www.gtexportal.org/home/) or
using the Haploreg data.
SNP-SNP Interaction Analysis
We also were interested in testing whether NFκB-related SNPs
could interact with each other to modify the risk of IA using the
multifactor dimensionality reduction (MDR) software. A detailed
description of the MDR method has been reported elsewhere
(Ritchie et al., 2003; Moore, 2004). A 10-fold cross-validation
analysis (exhaustive search) and permutation testing were used
to confirm the best interaction models. MDR models were
considered statistically significant at P < 0.05 (P sign). Statistical
significance of each particular model was then re-evaluated
using a 1.000-fold permutation test to compare observed
testing balanced accuracies with those expected under the null
hypothesis of no association (using theMDR permutation testing
module 0.4.9 alpha). Interactions were visualized by constructing
an interaction dendrogram according to the method described
by Moore et al. (Moore, 2004). MDR software and MDR
permutation testing module are open-source and freely available
from http://www.epistasis.org.
RESULTS
In this population-based case-control study a total of 834
hematological patients were recruited. Demographic and clinical
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TABLE 2 | Demographic and clinical characteristic of IA and non-IA patients.
aspBIOmics consortium + UHS-GHV-PCR-AGA-UCSC-MORE populations
Overall (n = 834) IA patients (n = 157) Non-IA patients (n = 677) P-value
DEMOGRAPHIC VARIABLES
Age 52.89 ± 15.95 53.78 ± 15.37 52.69 ± 16.07 NS
Sex ratio (male/female) 1.28 (466/362) 1.86 (99/53) 1.18 (367/309) 0.015
HEMATOLOGICAL DISEASE
AML 571 (68.62) 112 (71.33) 459 (68.00) NS
ALL 77 (09.25) 18 (11.46) 59 (08.74) NS
Other 184 (22.11) 27 (17.19) 157 (23.25) NS
HSCT 380 (45.56) 72 (45.85) 308 (45.49) NS
PROPHYLAXIS*
Ever use of prophylaxis 386 (46.28) 56 (35.67) 330 (48.74) 0.006
Never use of prophylaxis 232 (27.81) 54 (34.39) 178 (26.29) 0.006
HSCT, Hematopoietic stem cell transplantationl; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; UHS, University hospital of Salamanca (Spain); GHV, General hospital
of Valencia (Spain); PCRAGA clinical trial (EU clinical trial number: 2010-019406-17); UCSC, Università Cattolica del S. Cuore, Rome; MORE, University of Modena and Reggio Emilia,
AOU Policlinico, Modena (Italy). P values ≤ 0.05 were considered significant and are highlighted in bold.
*Some patients had several prophylactic drugs.
Data on underlying disease and sex was not available for 2 and 6 patients, respectively.
Prophylaxis status was unknown for 216 patients.
characteristics of these patients are summarized in Table 2. IA
and non-IA patients had similar age but male patients were more
prone to develop IA than females (male/female ratio = 1.86 vs.
1.18, P = 0.015). HSCT was common and equally distributed
between IA and non-IA groups (45.85 vs. 45.49%) and the
underlying disease (hematological disorder) was also uniform
between both groups (Table 2). As expected, patients without
prophylaxis were more prone to develop IA compared to those
patients who take antifungal drugs (23.28 vs. 14.51%; Table 2).
All SNPs were in Hardy-Weinberg in the control group
with the exception of the RELrs13031237 that was excluded from
further analyses (non-IA; P < 0.001). Allele and genotype
frequencies of selected SNPs were in line with those reported
in Hapmap. Logistic regression analysis adjusted for age, sex,
country of origin, allo-HSCT, and underlying disease showed
that none of the selected SNPs was significantly associated with
the risk of IA according to codominant, dominant, recessive
and log-additive models of inheritance (Table 3). In addition,
although prophylaxis status was only partially available in our
population (n = 618), no significant changes in association
estimates were observed when this clinical variable was included
as covariate for adjustment (data not shown). No significant
associations between the NFκB1, NFκB2, cRel, RelB, and IRF4
polymorphisms and IA risk were also found in an allo-HSCT-
restricted analysis considering donor genotypes and IA episodes
occurred after transplantation (Table 4). Although our statistical
power was limited (Supplementary Table 1), we found a fairly
weak association of the IRF4rs12203592T/T genotype with the risk
of developing the infection at the nominal significance level of
P < 0.05. Carriers of the IRF4rs12203592T/T genotype showed a
six-fold increased risk of developing IA when compared with
patients carrying the wild type C-allele (ORREC = 6.24, 95%CI
1.25–31.2, P = 0.026). Interestingly, we found that the presence
of the minor allele of the rs12203592 (T) strongly correlated
with IRF4 mRNA expression levels in whole blood samples and
Epstein-Barr virus (EBV)-transformed lymphocytes (P = 6.0 •
10−7 and P= 3.0 • 10−7, respectively), which suggested a possible
functional role of this polymorphism. Based on these interesting
results, we decided to explore the potential functional impact
of this polymorphism using Haploreg and ENCODE annotation
data. This analysis revealed that the IRF4rs12203592 SNP resides
on a strong enhancer and near of an active promoter that
might constitute a regulatory element for IRF4. In addition, this
analysis showed that this intronic polymorphism was predicted
to change binding motifs for NFκB, HDAC2, and HMG-IY,
which are proteins implicated in the transcriptional regulation of
multiple innate and adaptive immune-related genes (Liu et al.,
2001; Hayden et al., 2006; Falkenberg and Johnstone, 2014).
In line with the findings suggesting a functional role of this
variant, we also found that the rs12203592 SNP mapped among
promoter and enhancer histone marks in different primary T-cell
subtypes (TCD8+, TCD4+, Treg, and Th17) of different origin
(peripheral blood, hematopoietic stem cells, cord blood, etc.)
but also in primary B-cells, natural killer cells and monocytes.
Although at this point it was tempting to speculate that the
IRF4rs12203592 SNP might play a role in modulating the risk
of developing IA likely through the regulation of IRF4 mRNA
expression levels, the association of this SNP with IA risk did
not remained significant after correction for multiple testing (P
= 0.001; Table 4) and, therefore, requires further confirmation.
In agreement with the single-SNP analysis, haplotype association
analysis showed fairly weak associations of the IRF4AATC and
IRF4GGTC haplotypes (not including the IRF4rs12203592T risk
allele) with a decreased risk of IA. However, these associations
were of similar magnitude to the one observed for the
IRF4rs12203592 SNP in the single-SNP analysis (OR= 0.28, 95%CI
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TABLE 3 | Association estimates for NFκB-related polymorphisms and IA.
Variant_dbSNP Gene Effect-allele OR (95% CI)a Pvalue OR (95% CI)
b Pvalue OR (95% CI)
c Pvalue
rs4648110 NFκB1 A 0.69 (0.46–1.03) 0.07 0.73 (0.30–1.81) 0.50 0.74 (0.53–1.04) 0.08
rs12769316 NFκB2 A 0.87 (0.57–1.31) 0.50 0.79 (0.23–2.73) 0.70 0.87 (0.61–1.26) 0.48
rs1056890 NFκB2 T 1.41 (0.94–2.10) 0.10 1.01 (0.58–1.76) 0.96 1.19 (0.90–1.57) 0.23
rs11574851 NFκB2 T 1.52 (0.89–2.60) 0.13 1.47 (0.15–14.5) 0.74 1.46 (0.89–2.40) 0.14
rs842647 cREL G 0.92 (0.63–1.34) 0.67 1.03 (0.50–2.14) 0.93 0.95 (0.71–1.29) 0.77
rs13017599 cREL A 0.78 (0.54–1.13) 0.18 1.12 (0.67–1.88) 0.66 0.90 (0.69–1.18) 0.47
rs7119750 RELA T 0.94 (0.61–1.46) 0.80 0.90 (0.19–4.26) 0.89 0.95 (0.64–1.41) 0.79
rs2288918 RELB C 1.18 (0.80–1.73) 0.40 0.57 (0.30–1.09) 0.09 0.97 (0.73–1.28) 0.81
rs1877175 IRF4 A 0.82 (0.56–1.22) 0.34 0.59 (0.22–1.58) 0.30 0.82 (0.59–1.14) 0.24
rs1050975 IRF4 G 1.00 (0.61–1.63) 0.99 2.69 (0.75–9.61) 0.13 1.10 (0.72–1.68) 0.67
rs7768807 IRF4 C 1.33 (0.92–1.94) 0.13 1.26 (0.66–2.40) 0.48 1.24 (0.93–1.65) 0.14
rs12203592 IRF4 T 1.01 (0.66–1.53) 0.97 2.14 (0.64–7.19) 0.22 1.07 (0.74–1.56) 0.72
OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism. Estimates were adjusted for age, sex, country of origin, allo-SCT, and underlying disease. P < 0.0011 was
defined as multiple testing significance threshold.
aEstimates according to a dominant model of inheritance.
bEstimates according to a recessive model of inheritance.
cEstimates according to an additive model of inheritance.
TABLE 4 | Association estimates for NFκB-related polymorphisms and IA in HSCT patients (n = 239).
Variant_dbSNP Gene Effect-allele OR (95% CI)a Pvalue OR (95% CI)
b Pvalue OR (95% CI)
c Pvalue
rs4648110 NFκB1 A 1.04 (0.51–2.12) 0.92 2.99 (0.65–13.7) 0.16 1.19 (0.65–2.18) 0.57
rs12769316 NFκB2 A 1.29 (0.60–2.76) 0.51 NA (NA–NA) NA 1.16 (0.57–2.37) 0.67
rs1056890 NFκB2 T 1.42 (0.67–3.00) 0.36 1.32 (0.44–3.96) 0.63 1.29 (0.75–2.24) 0.36
rs11574851 NFκB2 T 1.59 (0.56–4.53)* 0.38 NA (NA–NA) NA NA (NA–NA) NA
rs842647 cREL G 0.81 (0.40–1.64) 0.55 0.94 (0.23–3.74) 0.93 0.86 (0.48–1.53) 0.61
rs13017599 cREL A 0.84 (0.42–1.68) 0.62 1.50 (0.61–3.67) 0.38 1.03 (0.63–1.68) 0.91
rs7119750 RELA T 0.53 (0.22–1.24) 0.14 NA (NA–NA) NA 0.52 (0.23–1.18) 0.12
rs2288918 RELB C 1.17 (0.58–2.36) 0.66 0.86 (0.33–2.26) 0.76 1.04 (0.64–1.68) 0.88
rs1877175 IRF4 A 0.68 (0.32–1.44) 0.32 0.69 (0.08–6.00) 0.74 0.72 (0.37–1.40) 0.33
rs1050975 IRF4 G 0.65 (0.26–1.66) 0.37 2.60 (0.37–18.4) 0.34 0.84 (0.39–1.80) 0.66
rs7768807 IRF4 C 0.73 (0.35–1.51) 0.39 0.95 (0.30–3.03) 0.93 0.82 (0.47–1.44) 0.49
rs12203592 IRF4 T 1.04 (0.49–2.20) 0.91 6.24 (1.25–31.2) 0.026 1.33 (0.72–2.47) 0.36
OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism; NA, not applicable. Estimates were adjusted for age, sex, country of origin, and underlying disease. P <
0.05 in bold. P < 0.0011 was defined as multiple testing significance threshold.
aEstimates calculated according to a dominant model of inheritance.
bEstimates calculated according to a recessive model of inheritance.
cEstimates calculated according to an additive model of inheritance.
*Association estimates are referred to heterozygotes. Homozygotes for the rare allele were not found in the HSCT cohort.
0.08–0.95, P = 0.042 and OR = 0.04, 95%CI 0.00–0.71; Table 5)
suggesting that the haplotypic effect was due to this intronic
variant.
Finally, given the involvement of physiological complexes
(p50/p65, p52/RelB, and p65-c-Rel) in the activation of the NFκB
signaling pathway and the role of the p52/RelB complex in the
transcriptional activation of the IRF4 (Boddicker et al., 2015),
we also decided to investigate whether NFκB-related SNPs might
interact to each other tomodify the risk of IA. Results of theMDR
analysis evaluating all possible combinations among the NFκB-
related SNPs are shown in Table 6 and Figure 1. The best model
suggested an interaction between the RELrs842647,NFκB2rs1056890,
IRF4rs7768807, and RELrs13017599 SNPs to synergistically increase
the risk of developing IA (TA = 0.5488, PSign = 0.0010).
Although this model was the best to predict IA and presented
a high cross validation consistency (CVC) (9/10), it did not
remain statistically significant following 1000-fold permutation
test (P = 0.31). In addition, we found a significant 2-locus
interaction model including theNFκB2rs1056890 and IRF4rs7768807
SNPs to increase the risk of getting the infection (TA = 0.5353,
PSign = 0.0010) but this interaction model also failed to
retain statistical significance after 1000-fold permutation test
(P = 0.47; Table 6). None of the best models included the
IRF4rs12203592 SNP.
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TABLE 5 | Haplotype association analysis and risk of IA.
Overall population (N = 834) HSCT population (N = 239)
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A G C C 0.1948 1.32 (0.90–1.95) 0.16 A G C C 0.2236 0.73 (0.34–1.56) 0.41
A G T T 0.1094 1.12 (0.64–1.93) 0.70 A A T C 0.1240 0.28 (0.08–0.95) 0.042
A A T C 0.1075 0.76 (0.42–1.40) 0.39 A G T T 0.1214 0.95 (0.38–2.37) 0.92
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aEstimates calculated according to a dominant model of inheritance and adjusted for age, sex, country of origin, allo-SCT and underlying disease.
bEstimates calculated according to a dominant model of inheritance and adjusted for age, sex, country of origin and underlying disease.
DISCUSSION
The NFκB pathway is implicated in fostering a wide variety of
physiological processes such as immune cell turnover (Hayden
et al., 2006), inflammation (Karin and Greten, 2005), T-cell
differentiation (Th1, Th2, Th17, and Treg subsets; Oh andGhosh,
2013), DC maturation (Burkly et al., 1995; Abe et al., 2003),
cell apoptosis (Wang et al., 1998; Karin and Greten, 2005),
cell adhesion (Chen et al., 1995; Lockyer et al., 1998; Chiang
et al., 2008), and angiogenesis (Beinke and Ley, 2004). In the
presence of fungal pathogens such as Aspergillus fumigatus,
the canonical NFκB pathway involving NEMO-IKKα-IKKβ
and NFκB-p50/p65 complexes can be activated by membrane
pattern recognition receptors (PRRs) such as toll-like receptors
(TLRs; Mambula et al., 2002; Bellocchio et al., 2004; Roeder
et al., 2004), C-type lectin receptors (CLRs; Serrano-Gómez
et al., 2004; LeibundGut-Landmann et al., 2007; Gringhuis
et al., 2009; Rivera et al., 2011; Saijo and Iwakura, 2011),
cytokine receptors (IL1R, TNFRs) (Bozza et al., 2014), or
soluble PRRs like pentraxins (PTX3; Garlanda et al., 2002) that
leads to the immediate secretion of pro-inflammatory cytokines
(TNF, IL1α, IL1β, IL6, IL12; Nicholson et al., 1996; Roeder
et al., 2004), chemokines (CCL2, CCL3, CXCL2 and CXCL10;
Shahan et al., 1998; Phadke and Mehrad, 2005; Reid et al.,
2009), and reactive oxygen species (ROS; superoxide, hydroxyl
radical, nitric oxide; Philippe et al., 2003; Chiang et al., 2008)
but also to the expression of specific immune receptors and
cell surface adhesion molecules (VCAM-1, E-Selectin; Akira
et al., 2001; Chiang et al., 2008; Gringhuis et al., 2009).
In addition, binding of fungal compounds to C-type lectins
(Dectin-1 and Dectin-2) and the activation of certain TNF
family cytokines (CD40L, BAFF, or LT-β) observed during
fungal infections leads to the activation of the non-canonical
NFκB pathway (p52/RelB), which is implicated in B-cell and
DC maturation (Hu et al., 2011; Sun, 2012) and γδTh17 cell
development (Powolny-Budnicka et al., 2011) but also in the
control of the expression of a wide range of immune-related
genes (Geijtenbeek and Gringhuis, 2009; Vallabhapurapu and
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TABLE 6 | Multifactor dimensionality reduction analysis summary.
Model TA Sign test (P-value) P-value* CVC
1 IRF4rs7768807 0.5408 9 (0.0107) 0.39 9/10
2 NFκB2rs1056890, IRF4rs7768807 0.5353 10 (0.0010) 0.47 8/10
3 RELrs842647,NFκB2rs1056890, IRF4rs7768807 0.4996 6 (0.0547) 0.84 4/10
4 RELrs842647,NFκB2rs1056890, IRF4rs7768807,RELrs13017599 0.5488 10 (0.0010) 0.31 9/10
TA, Testing accuracy; CVC, Cross-validation consistency.
Cross-validation and permutation testing were used to identify the best models. All possible two-way SNP interactions were tested using 10-fold cross-validation and the exhaustive
search. The model with the highest testing balanced accuracy (TA) and cross validation consistency (CVC) was selected as “best model.” Statistical significance was evaluated by the
Sign test and confirmed using a 1.000-fold permutation test to compare observed testing balanced accuracies with those expected under the null hypothesis of no association (using
the MDR permutation testing module 0.4.9 alpha).*1000-fold permutation test (α = 0.001, TA = 0.6370; α = 0.01, TA = 0.5984; α = 0.05, TA = 0.5830; α = 0.10, TA = 0.5717).
FIGURE 1 | Interaction dendrogram. The interaction dendrogram reveals no significant interactions among the studied SNPs to modulate the risk of IA.
Karin, 2009; Plato et al., 2013). On the other hand, it has recently
been suggested the existence of a CD30-p52/Relb-IRF4 loop to
regulate the NFκB pathway and cell proliferation (Boddicker
et al., 2015) and a role of IRF4 in modulating the differentiation
of different DC (Bajaña et al., 2016) and Th17-mediated immune
responses against A. fumigatus (Schlitzer et al., 2013).
Considering the central role of the PRRs-NFκB pathways and
IRF4 in the immune responses against A. fumigatus (Oh and
Ghosh, 2013; Schlitzer et al., 2013; Williams et al., 2013) and
those studies suggesting that genetic host factors may account
for differences in susceptibility to IA (Ok et al., 2011; van der
Velden et al., 2011), we decided to investigate the link between
genetic polymorphisms within NFκB1, NFκB2, RelA, RelB, Rel,
and IRF4 genes and the risk of IA. In spite of the growing
number of studies assessing the role of genetic polymorphisms
within PRRs (TLR2, TLR4, TLR9, Dectin-1, Dectin-2, DC-SIGN,
PTX3; Kesh et al., 2005; Bochud et al., 2008; Pamer, 2008; Cunha
et al., 2010, 2011, 2014; Chai et al., 2011; Sainz et al., 2012;
Grube et al., 2013; Wojtowicz et al., 2015b), cytokines (IL1, IL10,
IFNG; Sainz et al., 2007a, 2008a; Lupiañez et al., 2015), and
their receptors (IL4R, TNFR1, and TNFR2; Sainz et al., 2007b,
2010; Lupiañez et al., 2015) in determining the susceptibility to
invasive fungal infections, this is the first study that attempts to
evaluate the impact of polymorphisms within NFκB1, NFκB2,
RelA, RelB, REL, and IRF4 genes on the risk of developing IA. Our
data showed no significant overall associations between selected
SNPs and IA infection. The best result was the association of
the IRF4rs12203592 SNP with an increased risk of IA in HSCT
patients that suggested a weak effect of this locus on the risk of
IA that might become evident only in those patients with a more
profound degree of immunosuppression. However, despite the
potential interest of these results and the evidences supporting
a functional role of the IRF4rs12203592 variant in regulating IRF4
mRNA expression and thereby modulating the NFκB pathway
(Boddicker et al., 2015) and IRF4-dependent immune responses
(Schlitzer et al., 2013; Bajaña et al., 2016), the association of
this variant did not remain significant at the experiment-wide
significance threshold, suggesting that the association of this
polymorphism with IA could be due to chance. Haplotype
analysis showed a small effect of common haplotypes on IA risk
but the magnitude of these effects suggested that the observed
association was likely due to the IRF4rs12203592 SNP rather than
the combined effect of the IRF4 SNPs. In addition, when we
evaluated whether there was any significant interaction among
the SNPs analyzed, we did not observe any consistent interaction
model that could affect the risk of developing IA.
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In conclusion, this case-control study does not provide
strong evidence of a relationship between polymorphisms within
NFκB1, NFκB2, cRel, RelB, and IRF4 genes and IA risk.
Nonetheless, given the limited statistical power of the HSCT-
stratified analysis (80% to detect odds ratio of 2.1 at α = 0.001
for a SNP with a frequency of 0.25, dominant model) and
the evidences suggesting a functional role of the IRF4rs12203592
SNP, we cannot dismiss the possibility of a small but still real
effect of this variant or its haplotypes on the risk of IA in
HSCT patients. Future case-control population-based studies
conducted in larger HSCT populations are now warranted to
further evaluate whether the IRF4 locus may have a role in
determining the susceptibility to IA.
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